KKR completes $9.9B purchase of Envision

Private equity firm KKR has completed its acquisition of Envision Healthcare Corporation for a deal valued at $9.9 billion. The deal was previously announced in June.

Envision, a physician-led services and post-acute care and ambulatory surgery services provider, is now a wholly owned subsidiary of KKR. Envision stockholders will receive $46 per share of Envision common stock under terms of the deal. The company’s stock ceased trading on the New York Stock Exchange Friday as KKR took Nashville, Tennessee-based Envision private.

Envision had merged with Amsurg in 2016, making the entity a major healthcare provider in the nation. KKR also originally considered entering into the deal with for-profit hospital giant HCA Healthcare to potentially purchase the ambulatory surgery business, AmSurg, but HCA was not involved in the final deal.

The deal underscores the high-level interest from private equity in the healthcare space. Over the last several years, the industry has seen an influx of private equity investors looking for ways to add value to healthcare companies of all types. This rising interest has also helped valuations in the space rise rapidly.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

California-based Acutus Medical has said its ongoing agreement to manufacture and distribute left-heart access devices for Medtronic is the company's only source of revenue. 

The scam took place over a period of seven years, resulting in Medicare being billed for more than $70 million in fraudulent claims for unnecessary scans. 

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.